Placental Stem Cell Immunomodulation for Inflammatory Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases caused by unwanted or harmful immune responses, such as inflammatory bowel disease, graft-versus-host disease, and multiple sclerosis, often fail to provide adequate relief or have significant side effects, highlighting the need for more effective immunomodulatory therapies.
Innovation Solution
The use of CD10+, CD34−, CD105+, CD200+ placental stem cells, or cells expressing specific markers like CD73, CD105, and HLA-G, which are administered to suppress immune cell activity and promote immunomodulation, thereby reducing inflammation and disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional immunosuppressive treatments are used, then immune response suppression is achieved, but significant side effects occur
Solution Approach 1:
The patent uses placental stem cells as an intermediary substance to mediate between the immune system and the therapeutic goal. These stem cells suppress harmful immune responses through paracrine signaling and immunomodulation without causing the severe side effects of traditional immunosuppressants, acting as a biological mediator that achieves immune suppression with improved safety profile
Solution Approach 2:
The patent changes the therapeutic parameter from chemical immunosuppressants to biological stem cell therapy. By administering placental stem cells that express specific markers (CD10+, CD34-, CD105+, CD200+), the treatment achieves immune suppression through biological mechanisms rather than pharmacological inhibition, thereby reducing toxicity while maintaining effectiveness
2Reliability
If current immunomodulatory therapies are applied, then some disease relief is provided, but adequate relief is not achieved
Solution Approach 1:
The placental stem cells administered in this patent possess inherent immunomodulatory capabilities that enable them to self-regulate and adapt to the patient's immune environment. The cells express specific surface markers (CD10+, CD34-, CD105+, CD200+) that facilitate their integration and functional activity, allowing them to provide sustained therapeutic effect without requiring external modulation or adjustment
Data Source
AI summary
Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.